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Immunization of piglets with two different European-type modified live vaccines against porcine reproductive and respiratory syndrome
(PRRS) virus produced different outcomes. After vaccination, pigs became viremic (42 days), neutralizing antibodies did not develop, and
frequencies of virus-specific gamma-interferon-secreting cells (IFN-γ-SC) were low. Levels of interleukin-10 (IL-10) produced by peripheral
blood mononuclear cells (PBMC) seemed to inversely correlate with interferon-gamma responses. After a challenge with a virulent Spanish
strain, one vaccine (V3) protected piglets against viremia while the other (V1) did not. The vaccine V3 induced the highest IFN-γ-SC
frequencies. IL-2, IL-4 or transforming growth factor-beta responses were not detected at any time for neither of the vaccines. In contrast,
haptoglobin rose in sera of viremic pigs after the challenge. These results indicated a strong involvement of IFN-γ, and maybe IL-10, in the
development of immunity against PRRS virus.
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Porcine reproductive and respiratory syndrome (PRRS)
emerged in Europe in the early years of the 1990 decade and
rapidly spread all over the continent becoming one of the major
causes of economic losses for swine producers. Simultaneously,
the disease emerged in USA with a similar impact on pig
production. This syndrome, caused by an arterivirus (Meulen-
berg et al., 1994), is characterized in its reproductive form by
abortions, stillbirths and weakly born piglets and, in young pigs,
causes pneumonia and weight gain losses. PRRS virus (PRRSV)
is a small positive-stranded polyadenylated RNA virus that
contains nine open reading frames (ORFs). ORFs 1a and 1b
comprise 80% of the genome and encode the RNA polymerase;
ORFs2 to5 encode four structural glycoproteins (GP2,GP3,GP4⁎ Corresponding author. Centre de Recerca en Sanitat Animal (CReSA),
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doi:10.1016/j.virol.2006.03.046and GP5) and a small non-glycosylated protein called 2b (Wu et
al., 2005); ORF6 encodes a non-glycosylated integral membrane
protein (M) and ORF7 encodes the nucleocapside protein (N)
(Conzelmann et al., 1993; Meulenberg et al., 1997; Snijder and
Meulenberg, 1998). Currently, it is known that two distinct
genotypes of the virus exist, the European and the American, that
share only 55–80% similarity (Meng et al., 1995).
Soon after the discovery of the virus vaccines were
marketed. The first ones were a modified live virus (MLV)
vaccine called RespPRRS made of an American-type strain
(Christopher-Hennings et al., 1997; Dee and Joo, 1997;
Mengeling et al., 1996), and an inactivated vaccine called
Cyblue, made of a European strain (Plana-Duran et al., 1997).
From then, several vaccines, both attenuated and inactivated,
have been commercialized.
Notwithstanding, none of the vaccines can claim full
protection against the disease. On one hand, PRRSV, either
wild type or attenuated, induces a low level of cell-mediated
immunity (Meier et al., 2003) and neutralizing antibodies (NA)
Table 1
Percentages of similarity between the PRRSV strains used in the study
LV V1 V3 VP21
ORF 2
LV – 94.6 98.0 94.6
V1 94.6 – 94.3 98.3
V3 98.0 94.3 – 93.9
VP21 94.6 98.3 93.9 –
ORF 3
LV – 94.2 98.3 94.0
V1 94.2 – 92.5 99.4
V3 94.2 92.5 – 93.3
VP21 94.4 99.6 93.9 –
ORF 4
LV – 94.2 99.0 94.5
V1 94.2 – 94.2 99.2
V3 99.0 94.2 – 93.5
VP21 94.5 99.2 94.5 –
ORF 5
LV – 94.9 98.9 94.5
V1 94.9 – 94.4 99.6
V3 98.9 94.4 – 94.0
VP21 94.5 99.6 94.0 –
ORF 6
LV – 97.7 97.7 96.9
V1 97.7 – 100 98.6
V3 97.7 100 – 98.6
VP21 96.9 98.6 98.6 –
ORF 7
LV – 96.6 100 96.3
V1 96.6 – 96.6 99.7
V3 100 96.6 – 96.3
VP21 96.3 99.7 96.3 –
Lelystad virus (LV, Genbank accession number M96262) was used as a
reference.
LV = Lelystad virus, V1 = Modified live vaccine 1, V3 = Modified live vaccine
2, VP21 = wild-type Spanish PRRSV strain used for the challenge.
Table 2
Evolution of viremia in vaccinated pigs as determined by RT-nested PCR
Group Days post-vaccination
0 7 14 21 28 42 63 a 70 91
G1 0 5 4 5 2 1 0 4 0
G2 0 5 3 3 1 2 0 0 0
a At 63 days post-vaccination, both groups were challenged with 106 TCID50
of a wild-type Spanish PRRSV strain (VP21).
250 I. Díaz et al. / Virology 351 (2006) 249–259do not develop until a late phase of the infection (Meier et al.,
2003; Vezina et al., 1996; Yoon et al., 1995). In addition, the
cytokine imbalance after a vaccination or an infection suggests a
possible downregulation of many cytokines (Royaee et al.,
2004; Van Reeth et al., 1999). On the other hand, genetic
diversity of PRRSV is thought to influence the efficacy of
vaccines under field conditions (Labarque et al., 2004; Pesch et
al., 2005) although some degree of cross protection exists
(Mengeling et al., 2003a, 2003b). With this panorama, the
development of improved vaccines needs a deeper understand-
ing of the immunity against PRRSV.
Up to date, only one report has dealt with the evolution of the
immune responses, both humoral and cellular, after vaccination
with a European type PRRS-modified live vaccine (MLV)
(Sipos et al., 2003). However, that study was done with only one
vaccine, did not challenge the animals and did not evaluate
frequencies of IFN-γ-secreting cells (IFN-γ-SC), a parameter
that seems to be related to protection (Meier et al., 2003). The
aim of the present study was to characterize the humoral and the
cellular responses of pigs in the course of a vaccination with twoEuropean-type PRRS-MLVvaccines and after a challengewith a
European PRRS wild-type virus.
Results
Virus sequencing and phylogenetic analysis
Similarity between vaccines and VP21 strain was above
90%. Highest values were obtained for ORF7 and ORF6 and
lowest similarities corresponded to envelope glycoproteins
(Table 1). As a whole, VP21 was closer to V1 (both are
Spanish strains) than to V3. Interestingly, in ORF6 both
vaccines had exactly the same sequence that differed from
VP21 and LV by a change in the codon starting at position
14,402 in LV genome (cga → caa). That change would
correspond in the amino acid sequence to a substitution of an
arginine by a glutamine.
Detection of PRRSV
Viral isolation attempts in PAM or MARC-145 cells from
blood samples taken after vaccination were negative. In
contrast, all vaccinated animals were positive by nPCR at
least once during the first 6 weeks PV (Table 2). However,
viremia was probably low as, with a single round RT-PCR,
only six samples were positive during the first 14 days PV.
After the challenge, only G1 pigs were detected as positive by
nPCR (4/5) at 7 days post-infection (PI). Sequencing of the
nPCR amplicons showed the virus to be the VP21 strain. None
of the control pigs yielded nPCR-positive results or viral
isolation.
Hematology
In all three groups, hematological values remained between
normal ranges in the examined period (28 days PV). However,
some parameters significantly changed in vaccinated pigs at
first week PV, particularly for neutrophils, monocytes and
platelets (P < 0.05). Table 3 summarizes these results.
Humoral immune response
All pigs were seronegative to PRRSV at day 0. By using
ELISA, all vaccinated animals seroconverted by day 14 PV
(mean S/P ratio, 2.5 ± 0.2 for G1 and 2.4 ± 0.6 for G2) (Table 4).
ELISA titers peaked at 21 and 28 days PV for G1 and G2,
respectively (G1 = 3.2 ± 0.3 and G2 = 3.1 ± 0.3). After the
Table 3
Evolution of hematological parameters of vaccinated pigs from day 0 to day 28
post-vaccination
Parameter/
Group
Days post-vaccination
0 7 14 28
Total leukocytes
G1 16.1 ± 1.8 12.6 ± 2.9a 15.2 ± 2.0 13.4 ± 1.9
G2 16.1 ± 2.5 15.4 ± 1.0b 15.7 ± 4.4 12.5 ± 1.9
C 19.1 ± 4.2 12.8 ± 1.2a 12.2 ± 3.1 13.3 ± 2.2
%Neutrophils
G1 49.7 ± 6.4 36.7 ± 9.2a 16.6 ± 3.4 25.0 ± 5.1
G2 43.7 ± 7.1 28.4 ± 4.1b 21.8 ± 4.6 21.2 ± 7.0
C 53.8 ± 8.1 39.8 ± 3.9a 24.7 ± 6.9 20.0 ± 5.0
Neutrophils (103/μl)
G1 7.9 ± 1.3 4.6 ± 1.3a 2.4 ± 0.7 3.3 ± 0.6
G2 6.9 ± 1.2 3.3 ± 0.6a 3.3 ± 0.8 2.7 ± 1.1
C 10.3 ± 3.3 6.1 ± 0.9c 3.0 ± 1.0 2.7 ± 0.9
%Monocytes
G1 3.8 ± 1.2 3.2 ± 0.5a 6.0 ± 2.2 4.9 ± 1.4
G2 3.1 ± 1.5 6.6 ± 2.2b 4.9 ± 2.2 5.2 ± 1.8
C 3.2 ± 2.0 5.1 ± 0.4b 4.6 ± 1.4 5.1 ± 2.5
Monocytes (103/μl)
G1 0.6 ± 0.2 0.4 ± 0.1a 0.9 ± 0.4 0.7 ± 0.3
G2 0.5 ± 0.4 0.8 ± 0.3b 0.8 ± 0.7 0.7 ± 0.2
C 0.7 ± 0.5 0.8 ± 0.1b 0.5 ± 0.1 0.6 ± 0.5
Platelets (103/μl)
G1 431 ± 111 347 ± 72a 515 ± 110 383 ± 96
G2 434 ± 120 489 ± 43b 573 ± 114 465 ± 91
C 564 ± 95 422 ± 37b 470 ± 88 518 ± 101
Superindexes indicate statistical differences (Kruskal–Wallis test using the
Connover–Iman method for multiple comparisons; P < 0.05). Groups with the
same superscripted letter were statistically equal (a, b, or c). The remaining cells
subsets did not show statistical differences.
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With IPMA, positive results were only obtained from day 14 PV
onwards. The highest mean IPMA titers were seen at day 28 PI,
namely 91 days PV (log10 = 3.2 ± 0.1 for G1 and 3.0 ± 0.3 for
G2) (Table 4).
NA were only detected after the challenge (28 days PI) and
only in four vaccinated pigs (two animals/group) (Table 4).Table 4
Serological evolution of PRRS-MLV vaccinated pigs by ELISA (HerdCheck,
neutralization test (VNT)
Test Vaccine Days post-vaccination
0 7 14 21
ELISA no. of positive S/P ratio G1 Neg Neg 5/5 2.5 ± 0.2 5/5 3.2 ±
G2 Neg Neg 5/5 2.3 ± 0.6 5/5 2.9 ±
IPMA no. of positive (log10 titer) G1 Neg Neg 5/5 2.3 ± 0.3 5/5 2.4 ±
G2 Neg Neg 5/5 2.4 ± 0.2 5/5 2.4 ±
VNT no. of positive (log10 titer) G1 Neg Neg Neg Neg
G2 Neg Neg Neg Neg
Results are expressed as the mean ± standard deviation titer.
Unvaccinated animals were negative in all assays.
a At 63 days post-vaccination, both groups were challenged with 106 TCID50 ofBy using whole serum, the highest titer was log10
(titer) = 1.3 ± 0.0 (G2). Addition of fresh complement
increased titers by one dilution. All unvaccinated controls
remained seronegative to PRRSV in all tests throughout the
study.
IFN-γ-SC responses
Frequencies of IFN-γ-SC strongly depended on the strain
used for in vitro stimulation. When V1 was used, IFN-γ-SC
frequencies were very low in both vaccinated groups and did
not exceed 15 IFN-γ-SC/106 PBMC (Fig. 1). In contrast, use of
V3 for in vitro stimulation produced more clear results, with
mean frequencies of IFN-γ-SC that ranged from as low as 12/
106 PBMC (G1 at 28 days PV) to as high as 125/106 PBMC (G2
at day 28 PI, namely 91 days PV) (Fig. 2).
In vitro stimulation with VP21 strain produced results
similar to V3 but of a slightly lower intensity (Fig. 3). Taking
the results obtained with the VP21 stimulus as a common
reference to all groups, PRRSV-specific IFN-γ-SC were firstly
detected at 7 days PV (16/106 PBMC for G1 and 42/106
PBMC for G2) rising to >60/106 PBMC at 14 days PV
(P < 0.05 compared to controls). Then frequencies of PRRSV-
specific IFN-γ-SC decreased in both vaccinated groups (<40/
106 PBMC). At 63 days PV, G1 showed a mean value of 23
IFN-γ-SC/106 PBMC and G2 values increased up to 80 IFN-
γ-SC/106 PBMC (P < 0.05). After challenge (63 days PV), a
booster effect was observed in both vaccinated groups, but the
increase was more evident in G1. By day 28 PI, mean values
of PRRS-specific IFN-γ-SC were about 115/106 PBMC in
both groups.
Stimulation with V1, V3 or VP21 of PBMC from control
unvaccinated and uninfected pigs yielded negative results in
ELISPOT with no significant background.
Cytokine and haptoglobin ELISAs
In vitro stimulation of PBMC with V1, V3 or VP21 showed
no significant differences among groups for IL-2 or IL-4 in cell
culture supernatants (data not shown). Regarding IL-10, when
V1 was used as stimulus, PBMC of control pigs produced high
levels (110–322 pg/ml) (Fig. 4). In contrast, V3 and VP21 didIdexx Laboratories), immunoperoxidase monolayer assay (IPMA) and viral
28 42 63 a 70 91
0.3 5/5 3.1 ± 0.3 5/5 3.1 ± 0.3 5/5 2.8 ± 0.4 5/5 3.0 ± 0.1 5/5 3.0 ± 0.1
0.5 5/5 3.1 ± 0.3 5/5 3.1 ± 0.2 5/5 3.0 ± 0.4 5/5 2.9 ± 0.2 5/5 2.8 ± 0.1
0.2 5/5 2.8 ± 0.1 5/5 3.0 ± 0.3 5/5 2.6 ± 1.9 5/5 2.8 ± 0.4 5/5 3.2 ± 0.0
0.2 5/5 2.8 ± 0.2 5/5 2.9 ± 0.1 5/5 2.7 ± 0.3 5/5 2.8 ± 0.4 5/5 3.0 ± 0.3
Neg Neg Neg Neg 2/5 1.2 ± 0.1
Neg Neg Neg Neg 2/5 1.3 ± 0.0
a wild-type Spanish PRRSV strain (VP21).
Fig. 1. The figure shows the frequency of IFN-γ-secreting cells (ELISPOT) and IL-10 levels in peripheral blood mononuclear cell culture supernatants (ELISA) after
V1 in vitro stimulation in both vaccinated groups. For IL-10 results are expressed as the average of IL-10 secreted (pg/ml) (detection limit = 32 pg/ml), whereas
specific-virus IFN-γ-secreting cells are expressed as the average frequency of the specific-virus IFN-γ-secreting cells by 106 PBMC. *At 63 days post-vaccination,
both groups were challenged with 106 TCID50 of a wild-type Spanish PRRSV strain (VP21).
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P < 0.05).
When the specific IL-10 response was examined in
vaccinated pigs, stimulation of PBMC produced different
results depending on the virus used. In G1 pigs, stimulationFig. 2. The figure shows the frequency of IFN-γ-secreting cells (ELISPOT) and IL-1
V3 in vitro stimulation in both vaccinated groups. For IL-10 results are expressed
specific-virus IFN-γ-secreting cells are expressed as the average frequency of the spe
levels (P < 0.05). (b) G2 > G1 IFN-γ-secreting cells (P < 0.05). *At 63 days post-va
PRRSV strain (VP21).with V1 produced high levels of IL-10 until 42 days PV (150–
236 pg/ml); from this date on, IL-10 could not be detected
(Fig. 1). For G2 pigs, in vitro stimulation with V1 produced
lower levels of IL-10 that began to decline by day 21 PV and
became undetectable by day 70 PV. Stimulation of PBMC0 levels in peripheral blood mononuclear cell culture supernatants (ELISA) after
as the average of IL-10 secreted (pg/ml) (detection limit = 32 pg/ml), whereas
cific-virus IFN-γ-secreting cells by 106 PBMC. (a) G1 and G2 > Controls IL-10
ccination, both groups were challenged with 106 TCID50 of a wild-type Spanish
Fig. 3. The figure shows the frequency of IFN-γ-secreting cells (ELISPOT) and IL-10 levels in peripheral blood mononuclear cell culture supernatants (ELISA) after
wild-type Spanish PRRSV strain (VP21) in vitro stimulation in both vaccinated groups. For IL-10 results are expressed as the average of IL-10 secreted (pg/ml)
(detection limit = 32 pg/ml), whereas specific-virus IFN-γ-secreting cells are expressed as the average frequency of the specific-virus IFN-γ-secreting cells by 106
PBMC. (a) G1 and G2 > Controls IL-10 levels (P < 0.05). (b) G1 > G2 IL-10 levels (P < 0.05). (c) G2 > G1 IFN-γ-secreting cells (P < 0.05). *At 63 days post-
vaccination, both groups were challenged with 106 TCID50 of a wild-type Spanish PRRSV strain (VP21).
253I. Díaz et al. / Virology 351 (2006) 249–259with V3 produced low IL-10 values in all animals, except at
28 days PV, when these levels significantly increased in both
vaccinated groups (Fig. 2). Finally, use of VP21 as an in vitro
stimulus yielded two IL-10 peaks in G1 pigs (between 21 and
28 days PV and 7 days PI) and one peak in G2 pigs (between
28 to 42 days PV) (P < 0.05, compared to control group).Fig. 4. IL-10 levels in peripheral blood mononuclear cells culture supernatants (ELISA
strain (V1), PRRS-MLV made of a European strain (V3) and PHA stimulation in vitr
the average of IL-10 secreted (pg/ml) (detection limit = 32 pg/ml). (a) IL-10 levels a
(P < 0.05).Interestingly, this phase of higher ability of PBMC for
producing IL-10 after in vitro stimulation with the VP21
strain (between 21 and 42 days PV) corresponded to the lower
IFN-γ-SC values (Fig. 3).
None of the sera yielded positive results for IL-10 and
TGF-β. In contrast, serum haptoglobin levels in G1 increased) after wild-type Spanish PRRSV strain (VP21), PRRS-MLVmade of a Spanish
o assays of unvaccinated and uninfected pigs (controls). Results are expressed as
fter V1 in vitro stimulation always were significantly higher than V3 and VP21
254 I. Díaz et al. / Virology 351 (2006) 249–259significantly at 7 days PI (P < 0.05), returning to normality by
day 14 PI (Fig. 5).
Discussion
Several studies have reported that the immune response
against arteriviruses is unique in its features (Balasuriya and
MacLachlan, 2004; Cafruny et al., 1999; Meier et al., 2003).
Regarding PRRSV, it seems that both, humoral and cellular,
responses do not control the infection adequately. NA develop
slowly and usually appear after the resolution of viremia. In
addition, cell-mediated immunity also rises slowly, and virus-
specific IFN-γ-SC frequencies are low compared to other viral
pig diseases (Meier et al., 2003). Some authors suggested that,
in PRRS, immunity might play a secondary role and stated that
availability of permissive macrophages may determine the
outcome of the infection (Diaz et al., 2005; Xiao et al., 2004). A
similar hypothesis has been postulated for lactate dehydroge-
nase-elevating virus (LDV), a related arterivirus (Onyekaba et
al., 1989; Van den Broek et al., 1997).
Vaccines made of MLV or inactivated PRRSV are being
commercialized and have shown a relative efficacy (Mengel-
ing et al., 2003a, 2003b; Plana-Duran et al., 1997; Van
Woensel et al., 1998). Nevertheless, this is a controversial
issue. Firstly, because it is unclear how well vaccines prevent
the infection and how safe they are (Labarque et al., 2003;
Mengeling et al., 2003a, 2003b) and, secondly, because it is
thought that the genetic diversity of PRRSV can negatively
affect the field efficacy of vaccines (Labarque et al., 2004;
Meng, 2000).
In the present study, two European-type vaccines were
examined. To assess differences in protection, it was important
to evaluate the genetic similarity between them and the
challenge VP21 strain. As expected, main differences between
the PRRSV strains used were found in ORF3 and ORF5, whichFig. 5. Kinetics of serum haptoglobin as measured by ELISA in vaccinated and cont
with a wild-type Spanish PRRSV strain (VP21).are known to be the most variable regions in the PRRSV
genome (Pirzadeh et al., 1998; Forsberg et al., 2001).
Besides this, it is interesting to note that ORF6 of both
vaccine viruses shared a change corresponding to the codon
starting at position 14,402 in LV. This change (cga → caa)
produced a substitution of an arginine by a glutamine compared
to VP21 or LV. Grebennikova et al. (2004) showed that in the
American-type PRRSV strain NADC-8, a change in the
position 14,440 (alanine→ threonine) contributed significantly
to reduce viral virulence. In our case and theirs, one amino acid
present in virulent strains was substituted by a polar uncharged
one in the attenuated viruses. This finding supports the idea that
this site in ORF6 can be related to attenuation.
After vaccination, both G1 and G2 pigs became viremic, and
some animals remained so as late as 42 days PV. Sipos et al.
(2003) reported 3 weeks of viremia in piglets using one of the
European-type PRRSV MLV used in the present study. These
extended periods of viremia could significantly contribute to the
spread of vaccine virus in the pig population. This fact was
reported for American-type vaccines used in Europe (Morten-
sen et al., 2002; Storgaard et al., 1999). These results point out
the question of attenuation. Extended periods of viral replication
should not be interpreted as equivalent to virulence or vice
versa. As Xiao et al. (2004) suggested, in PRRS, viral
replication would occur as long as permissive macrophages
exist. Thus, with an attenuated PRRSV strain, that can be
thought to produce less intense cytolytic cycles, viral replication
should last a long time.
In our case, pigs vaccinated with V1 developed viremia
when infected with VP21, while in G2 pigs virus was not
detectable in blood after the challenge. Genetic similarity was
higher between V1 and VP21 (98.3–99.7%) than between V3
and VP21 (92.3–98.6%). That fact shows that, in our case, the
heterologous strain provided better protection than the homol-
ogous one. This apparent contradiction could be explained byrol pigs. (†)P < 0.05. *At 63 days post-vaccination both groups were challenged
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in the ability of each vaccine strain to induce PRRSV-specific
IFN-γ-SC. In addition, the capability of V1 to stimulate IL-10
responses might also have had a role.
Regarding the hematological parameters examined, we
observed some changes at 7 days PV, but all values remained
between the physiological ranges for pigs. This has also been
reported by Sipos et al. (2003).
By using ELISA, development of specific antibodies could
be seen at 14 days PV in all vaccinated pigs and titers remained
high throughout the experiment. Interestingly, ELISA titers did
not increase significantly after inoculation of the wild-type
strain even in viremic pigs. Some authors claimed (Johnson et
al., 2004) that the quantitation of the humoral response (total
antibodies) measured by ELISA can serve as an indicator of the
virulence of a given PRRSV strain. In the present case, using the
same ELISA than Johnson et al. (2004), titers after vaccination
reached a high of 3.15 (S/P ratio), similar to the values obtained
with the most virulent strain used in Johnson's work. In our
opinion, ELISA titers can not be used to measure virulence, at
least, when European-type PRRSV strains are evaluated.
In our study, vaccinated pigs did not develop NA before the
challenge. Meier et al. (2003), using a MLV vaccine made of an
American-type strain, needed two doses of the vaccine to induce
only in some animals low levels of NA. Although it seems that
high titers of NA could play a role in the outcome of the
infection (Lopez and Osorio, 2004) most experiments showed a
low, delayed and sporadic development of NA (Meier et al.,
2003; Mengeling et al., 1999; Vezina et al., 1996). However, as
it has been observed in other arterivirus such as LDV, viremia
can be cleared in absence of NA (Balasuriya and MacLachlan,
2004). In our experiment, G2 pigs achieved sterilizing
immunity without the need of detectable NA.
Regarding the cellular immune response using VP21 or V3
as stimuli, levels of IFN-γ-SC rose at 14 days PV, then were
erratic, and finally rose again at 63 days PV. This figure is
similar to the data reported by us in a previous experiment,
where unvaccinated pigs were experimentally infected with the
VP21 strain (Diaz et al., 2005).
Just before the challenge, stimulation of PBMC with VP21
produced 81 IFN-γ-SC/106 PBMC in G2, while the same
stimulation only produced 21 IFN-γ-SC/106 PBMC in G1.
After the challenge with VP21, G1 pigs became viremic (4/5)
while G2 pigs did not. Therefore, V1 vaccine demonstrated a
reduced ability to induce protective immune memory compared
to V3 vaccine. The remaining pig in G1 that did not develop
viremia had the higher IFN-γ-SC frequency at the day of
challenge (45 IFN-γ-SC/106 PBMC). These results add a strong
evidence for the role of the IFN-γ-SC in protection against
PRRSV infection in piglets. Recently, Lowe et al. (2005)
observed a strong correlation of cell-mediated immunity
measured by IFN-γ-SC with protection against reproductive
failure in sows of commercial herds as well. As discussed later,
V1 had a higher ability to induce IL-10 secretion, and this could
be have impaired the development of IFN-γ-SC. However, it
cannot be ruled out that the adjuvant used with V3 had an
influence on that observation although some authors denied theeffect of adjuvants in PRRSV immunization (Meier et al.,
2003).
Our results also showed that IFN-γ-SC frequencies were
extremely low when V1 was used for in vitro stimulation. This
was observed even in pigs vaccinated with V1. The impairment
of IFN-γ-SC responses when V1 was used as a stimulus could
be explained by the ability of V1 to induce the production of
high levels of IL-10 in PBMC. Since this IL-10 production was
seen in control pigs, it is reasonable to think that this was an
intrinsic characteristic of the V1 strain and did not involve
mechanisms of the adaptative immunity. Also, PBMC are
thought to be non-permissive cells for PRRSVand therefore, the
IL-10 release probably did not originate from viral replication in
blood cells. The explanation for this fact remains unclear but a
reasonable hypothesis is that IL-10 secretion was the result of
the interaction of some of the envelope glycoproteins, the most
variable part of the virus, with cellular receptors in monocytes
or lymphocytes. However, this is only a hypothesis to be tested
in further studies on PRRSV and immunity.
Regarding IL-10 secretion after recall PRRSV stimulation, it
could be seen that this cytokine peaked between days 14 and 42
PV depending on the group and the strain (V3 or VP21) used.
By day 63 PV, IL-10 was practically undetectable in cell culture
supernatants. Disappearance of IL-10 correlated with the
resolution of the viremia after vaccination. When G1 pigs
were challenged with VP21 and developed viremia, IL-10 rose
again. In a previous experiment (Diaz et al., 2005) we observed
that in pigs experimentally infected with VP21, viremia and
cessation of IL-10 production were also correlated. These facts
suggest either that replication of the virus induces IL-10 or,
alternatively, that IL-10 release sustains viral replication.
In the present experiment, as seen in control pigs, the
potential of IL-10 secretion of PBMC changed over time. Thus,
PHA stimulation produced some 700 pg/ml at 5 weeks of age
and, from 8 weeks of age on, the same stimulus only yielded
some 200–300 pg/ml. This fact indicated an influence of age on
the ability to secrete IL-10. Interestingly, when PBMC from
vaccinated pigs were stimulated in vitro with V1, a similar
pattern was seen, but production of IL-10 was lower. From
42 days PV, V1 stimulation of PBMC from vaccinated pigs
produced very low or undetectable IL-10 levels. Taken together,
these observations can be interpreted as a virus-specific
stimulation of PBMC that took place regardless of the immune
status of the pig. The explanation for that is not fully clear but
from 42 days PVon, frequencies of PRRSV-specific IFN-γ-SC
rose. This suggests a role for the Th1/Th2 balance in this
pattern.
Results for IL-2 and IL-4 responses did not show significant
differences between control and vaccinated pigs using any of
the viral strains. These data support the notion that some type of
immunomodulation takes place in the course of the infection or
vaccination (Royaee et al., 2004; Sipos et al., 2003).
Haptoglobin was only detected in sera of G1 animals after
the challenge with VP21. Those animals were the only ones
that developed viremia after the challenge. In our opinion,
haptoglobin release was probably linked to the tissular damage
caused by the wild virus but not by the replication of an
256 I. Díaz et al. / Virology 351 (2006) 249–259attenuated PRRSV strain. It is known that haptoglobin is
related with IL-6 release in inflammatory processes (Asai et
al., 1999).
In summary, the pattern of the evolution of both the
humoral and the cellular immune responses after a PRRSV
vaccination is very similar to that of a PRRSV infection in
piglets (Diaz et al., 2005). Vaccine V1 had the lowest capacity
to induce IFN-γ-SC and, in contrast, was able to stimulate a
very high IL-10 release from PBMC. After the challenge with
the virulent virus, the response of pigs vaccinated with V1
resembled that of an unvaccinated pig in terms of prevention
of viremia. This observation leads to the notion that IFN-γ-SC
most probably is the main factor in protecting against PRRSV
infection as well as that IL-10 release may hamper the
development of such IFN-γ-SC. Thus, the capacity of a given
PRRSV strain to induce a strong cell-mediated immunity,
measured as IFN-γ-SC, may be probably modulated by the
IL-10 release (Chung and Chae, 2003; Suradhat and
Thanawongnuwech, 2003; Suradhat et al., 2003; Diaz et al.,
2005). Once the modulation of the immune response
disappears, IFN-γ-SC frequencies rose and, when a given
frequency is reached, the pig will be protected (Lowe et al.,
2005). Nevertheless, this is only attained at late stage. On the
other hand, since the ability to produce IL-10 may change
with age, this host factor may also influence the outcome of
the immunization or the infection.
In addition, we saw that the protection afforded by a given
vaccine against a given PRRSV strain cannot be forecasted
only by a global view of the genetic similarity between the
vaccine virus and the challenge virus but, maybe, can be
forecasted by examining the specific ability of a given viral
strain to induce IFN-γ-SC and to modulate the immune
responses. In consequence, the development of an effective
vaccine for piglets should take into account the balance
between IL-10 induction and the development of IFN-γ-SC.
These data can be of critical importance to develop new and
better PRRS vaccines.
Materials and methods
Animals and housing
Thirteen healthy 3-week-old Landrace pigs were randomly
selected in a high health farm belonging to the Institut de
Recerca i Tecnologia Agroalimentària (IRTA, Barcelona,
Spain) that has historically been free of all major pig diseases
including PRRS. Animals were transported to the experimen-
tal facilities, randomly divided in three groups (G1, G2 and C)
and kept during 7 days to allow adaptation to the new
conditions. Before the start of the experiment, pigs were
examined for antibodies against porcine circovirus type 2,
Aujeszky's disease virus, porcine parvovirus, swine influenza
and Mycoplasma hyopneumoniae. All animals were seroneg-
ative for all of the abovementioned pathogens. Also, animals
were confirmed to be free of PRRSV, as determined by ELISA
(Herdcheck PRRS 2XR, IDEXX Laboratories, Westbrook ME,
USA).Vaccines and virus
Animals in group G1 (n = 5) were intramuscularly (IM)
vaccinated with 104.0 TCID50 of a MLV made of one Spanish
PRRSV strain (V1) using water as a vehicle (2 ml). G2 pigs
(n = 5) received 104.0 TCID50 of a commercial MLV made of
other European PRRSV strain (V3) (2 ml, IM) with an oil-in-
water adjuvant. Vaccines were diluted with the vehicles
recommended by each of the manufacturers. The remaining
three pigs were kept as controls (C) and received 2 ml of sterile
minimal essential medium (MEM) (Sigma, Alcobendas, Spain)
as a placebo.
The virulent PRRSV VP21 strain used for the challenge was
isolated in porcine alveolar macrophages (PAM) from sera of
naturally infected pigs during an outbreak of PRRS affecting a
breeding farm located in the north of Spain in December 1991.
That outbreak was characterized by abortions, stillbirths and,
later on, piglet mortality. The virus was shown to be of the
European genotype by sequencing of ORFs 2 to 7. Viral stock
was done by passage (n = 3) in PAM and titrated by means of
the immunoperoxidase monolayer assay (IPMA) according to
Wensvoort et al. (1991). Before to be used, the viral stock was
checked for bacterial contamination and for the presence of
other viruses.
At 63 days post-vaccination (PV), pigs in groups G1 and G2
were inoculated intranasally with 2 ml viral suspension
containing 106 TCID50/ml of PRRSV VP21 strain diluted in
sterile MEM, whilst pigs in group C only received 2 ml of sterile
MEM.
Virus sequencing and phylogenetic analysis
ORFs 2 to 7 of the vaccine viruses and challenge virus were
amplified by PCR using specific primer pairs (Table 5).
Sequencing was done using an ABI 3100 sequencer (Applied
Biosystems). Sequences were formatted and translated to amino
acid sequences. Alignments were done using ClustalW
software. As a reference, Lelystad virus (LV) sequence
(Genbank accession number M96262) was used. Nucleotide
sequences were deposited at Genbank under accession numbers
DQ009657-DQ009659 (ORF2); DQ009654-DQ009656
(ORF3); DQ067250, DQ064784, DQ064785 (ORF4);
DQ009647, DQ064787, DQ064788 (ORF5), DQ009651-
DQ009653 (ORF6) and DQ009648-DQ009650 (ORF7).
Samples
Blood samples were collected in duplicate (heparinized and
siliconized blood-collecting tubes) immediately before vacci-
nation and then at days 7, 14, 21, 28, 42, 63, 70 and 91 PV. Sera
were used for PRRSV isolation and specific RT-nested PCR
(nPCR), determination of humoral responses and evaluation of
haptoglobin, IL-10 and transforming growth factor-beta (TGF-
β) levels. Heparinized blood samples were used for hemato-
logical evaluation. Peripheral blood mononuclear cells (PBMC)
were also obtained from heparinized blood samples and used for
in vitro experiments.
Table 5
Oligonucleotides used for PCR amplification of different open reading frames
(ORFs) from PRRSV with the respective annealing temperatures and the
number of PCR cycles
Gene specificity Primer a Oligonucleotide
sequences (5′–3′)
Annealing
temperature (°C)
No. of
cycles
ORF2 L CTG GCA CAG AAT
TGC AGG TA
55 45
R GCA CAC TGATGA
GCC ATT GT
ORF3 L ACA ATG GCT CAT
CAG TGT GC
55 35
R TGA AGC CTT TCT
CGC TCA TT
ORF4 L AGC GTG ACC ATG
ATG AGT TG
55 39
R AAA AGC CAC CAG
AAG CAA GA
ORF5 L TGA GGT GGG CTA
CAA CCATT
55 35
R AGG CTA GCA CGA
GCT TTT GT
ORF6 L GTC CTC GAA GGG
GTT AAA GC
55 35
R CTG TCC TCC CCT
AGG TTG CT
ORF7 L GGC AAA CGA GCT
GTT AAA CG
55 35
R AAT TTC GGT CAC
ATG GTT CC
a L, left or forward primer; R, right or reverse primer.
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Serum samples were inoculated on MARC-145 and PAM
cultures and incubated at 37 °C in 5% CO2 for 90 min. Then
sera were removed, and MEM was added. Cultures were
incubated for three days at 37 °C in 5% CO2. Infection of
inoculated cells was determined by IPMA (Wensvoort et al.,
1991).
Besides viral isolation, sera were examined by nPCR.
Briefly, total RNA was extracted from 150 μl serum by using
a commercial system (Nucleospin RNA virus; Macherey-
Nagel, Düren, Germany). Total RNA was transcribed, and
cDNA was used in a first PCR round directed to viral ORF5
(Mateu et al., 2003). This first-round PCR had a sensitivity of
about 102 TCID50/ml of serum. PCR products were used in
an nPCR (forward primer, 5′-TCTTGCTTCTGGTGGCTTTT-
3′; reverse primer, 5′-CATGTTTGATGGTGACGAGG-3′)
that produced a 499-bp amplicon. Cycling parameters for
both PCRs were 94 °C for 45 s; 55 °C for 45 s; 72 °C for
45 s for a total of 35 cycles. Under these conditions, the
nPCR was considered to be able to detect <10 viral copies/ml
of serum.
Hematology
Hematological cell counts were done using an automated
system (Advia 120, Bayer) with protocols adapted to pig blood
samples.Humoral immune response
A commercially available ELISA (Herdchek PRRS 2XR,
Idexx Laboratories) was used to measure PRRSV-specific
antibodies. According to the manufacturer, sample to positive
control (S/P) ratios of >0.4 were considered positive. PRRSV
antibody titers were also determined in sera by using IPMA
(Wensvoort et al., 1991), using MARC-145 cells infected with
the PRRSV VP21 strain. Tests were done in duplicate.
NA were measured by the technique described by Jusa et
al. (1996) and Yoon et al. (1994). Tests were done in
triplicate by using whole serum, inactivated serum and serum
plus 10% fresh guinea-pig complement. Briefly, 50 μl of each
serum to be tested was diluted serially from 1/20 to 1/160 in
cell culture medium. Dilutions were mixed with 50 μl viral
suspension containing 200 TCID50 of the PRRSV strain
VP21 (with or without complement). Virus–serum mixtures
were incubated for 1 h at 37 °C and then added to MARC-
145 cultures in duplicate (96-well plates) and incubated for
3 days at 37 °C in 5% CO2. Infection of cell cultures was
revealed by using IPMA.
Isolation and culture of PBMC
PBMC were separated from whole blood by density-gradient
centrifugation with Histopaque 1.077 (Sigma). For PBMC
cultures, RPMI 1640 medium supplemented with 10% fetal calf
serum (Invitrogen, Spain), 1 mM non-essential amino acids
(Invitrogen), 1 mM sodium pyruvate (Invitrogen), 5 mM 2-
mercaptoethanol (Sigma), 50,000 IU/l penicillin (Invitrogen),
50 mg/l streptomycin (Invitrogen) and 50 mg/l gentamicin
(Sigma) was used. Trypan blue stain was used to assess
viability.
PRRSV-specific IFN-γ-SC
Frequencies of PRRSV-specific IFN-γ-SC in PBMC were
analyzed by an ELISPOTassay using commercial mAbs (Swine
IFN-γ Cytosets, Biosource Europe) according to a previously
reported method (Díaz and Mateu, 2005). Briefly, ELISA plates
(Costar 3590, Corning, USA) were coated overnight with
8.3 μg/ml IFN-γ capture antibody diluted in carbonate–
bicarbonate buffer (pH 9.6). Plates were then washed and
blocked for 1 h at 37 °C with 150 μl of PBS with 1% of bovine
serum albumin. After removal of the blocking solution, 5 × 105
PBMC were dispensed per well (50 μl) and stimulated with V1,
V3 or VP21 strains diluted in RPMI at a multiplicity of infection
(MOI) of 0.01. After 20-h incubation at 37 °C in a 5% CO2
atmosphere, cells were removed, and the biotinylated detection
antibody was added at 2.5 μg/ml (50 μl) and incubated for 1 h at
37 °C. The reaction was revealed by sequential incubation of
plates with streptavidin-peroxidase (1 h) and insoluble TMB
blue (Calbiochem, Spain). Unstimulated cells and phytohe-
magglutinin (PHA)-stimulated controls (10 μg/ml) were also
included.
To calculate the PRRSV-specific frequencies of IFN-γ-SC,
counts of spots in unstimulated wells were subtracted from
258 I. Díaz et al. / Virology 351 (2006) 249–259counts in virus-stimulated wells. Frequencies of IFN-γ-SC were
expressed as responding cells in 106 PBMC.
Cytokine (IL-2, IL-4, IL-10 and TGF-β) and haptoglobin
ELISAs
PBMC were seeded at a density of 2 × 106 cells per well
(250 μl) in 96-well plates and were mock stimulated or
stimulated with V1, V3 or VP21 strains (MOI of 0.01) or PHA
(10 μg/ml). After 24 h of incubation at 37 °C in 5% CO2, cell
culture supernatants were collected and frozen at −80 °C until
needed. Capture ELISAs were performed as reported previously
(Darwich et al., 2003; Díaz and Mateu, 2005) using commercial
pairs of mAbs (Swine IL-2, IL-4, and IL-10 cytosets, Biosource
Europe). The cut-off point of each ELISAwas calculated as the
mean optical density of negative controls plus three standard
deviations. Cytokine concentrations were calculated using the
linear regression formula from optical densities of the cytokine
standards provided by the manufacturer. IL-10 and TGF-β were
also measured in sera of experimental animals by using the
abovementioned ELISAs. Detection limits for both cytokines
were 32 pg/ml. Serum haptoglobin levels were determined by
means of ELISA (Haptoglobin assay phase range, Tridelta,
Ireland) according to the manufacturer's instructions.
Statistical analysis
The regression line of cytokine standards in ELISA was
calculated by using SPSS v12.0 (SPSS Inc., Chicago, USA).
Statistical comparisons between groups (Mann–Whitney/Krus-
tal–Wallis tests) were done by using Statsdirect v2.4.1. All tests
done in the study, as well as the statistical analysis, were
performed blind.
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